Watson Bio announcement recently. The company received the "Ethics Review Approval" from the Vaccine Clinical Trial Ethics Committee of the Yunnan Provincial Center for Disease Control and Prevention on "Evaluation of the Phase IIIB Clinical Trial of the Novel Coronavirus Variants mRNA Vaccine (S Protein Chimera) in people aged 18 years old and above who have completed 3 doses of inactivated COVID-19 vaccination. The review opinion is: After review by this Ethics Committee, it is agreed to carry out this study according to the approved clinical trial plan and related data.
As of the close of November 3, 2022, Watson Biologics (300142) closed at 41.75 yuan, down 2.27%, a turnover rate of 1.72%, a trading volume of 267,600 lots, and a trading volume of of 21.121 billion yuan. In terms of capital flow data, on November 3, the net outflow of main funds was 119 million yuan, the net inflow of hot money funds was 89.6003 million yuan, and the net inflow of retail funds was 29.3625 million yuan. In terms of margin financing and securities lending, the net inflow of financing was 54.4542 million in the past five days, and the balance of financing increased; the net inflow of margin financing was 120,500, and the balance of margin financing increased.
According to the financial report data in the past five years, Securities Star valuation analysis tool shows that Watson Bio (300142) has excellent competitive moats in the industry, poor profitability, and average revenue growth. There may be hidden financial concerns, and financial indicators that must be paid attention to include: accounts receivable/profit ratio, accounts receivable/profit ratio growth in the past three years, and inventory/revenue ratio growth. The stock has a good company index of 2.5 stars, a good price index of 2 stars, and a comprehensive index of 2 stars. (Indicators are for reference only, indicator range: 0 ~ 5 stars, the highest 5 stars) In the past 90 days, 7 institutions in this stock have given ratings, 24 html buy ratings, and 3 rated share ratings; the average target price of institutions in the past 90 days was 54.69.
Watson Bio (300142) main business: research and development, production and sales of vaccine products. The company's chairman is Li Yunchun. The company's general manager is Jiang Runsheng .
The top ten funds with heavy holdings in Watson Biologics are shown in the table below:
The fund with the largest holding is China Merchants Guozheng Biopharma Index (LOF) A, with a current scale of 13.817 billion yuan, with a latest net value of 0.6046 (November 3), down 0.89% from the previous trading day and 29.08% in the past year. The current fund manager of this fund is Hou Hao and Xu Rongman.
or above content was compiled by Securities Star based on public information and has nothing to do with the position of this site. Securities Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of this information (including but not limited to text, video, audio, data and charts). If there are any problems, please contact us. This article is a data compilation and does not constitute any investment advice to you. Investment is risky, so please make prudent decisions.
